ClinicalTrials.gg

Program

vosoritide

Also written as “BMN 111”, “Vosoritide” and “Vosoritide Injection”.

Its studies are mostly in Achondroplasia · Noonan Syndrome · Dwarfism, led by BioMarin Pharmaceutical.

Furthest: phase 3, since May 23, 201714 company-led studies, 7 open or runningNext primary completion: Dec 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioMarin Pharmaceutical147 open or runningphase 3since May 23, 2017Mar 14, 2012Dec 2027phase 2 · NCT04554940

Also a collaborator on its studies: icon-clinical-research.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Mar 14, 2012.

  1. Apr 18, 2013Phase 2 study in AchondroplasiaNCT02055157 · 35 enrolled · United States, Australia, France and more
  2. Feb 12, 2016Phase 2 study in AchondroplasiaNCT02724228 · 30 enrolled · United States, Australia, France and more
  3. May 23, 2017Phase 3 study in AchondroplasiaNCT03197766 · 121 enrolled · United States, Australia, Germany and more
  4. Dec 28, 2017Phase 3 study in AchondroplasiaNCT03424018 · 119 enrolled · United States, Australia, Germany and more
  5. Jun 14, 2018Phase 2 study in AchondroplasiaNCT03583697 · 75 enrolled · United States, Australia, Japan and more
  6. May 22, 2019Phase 2 study in AchondroplasiaNCT03989947 · 73 enrolled · United States, Australia, Japan and more
  7. Sep 14, 2020Phase 2 study in AchondroplasiaNCT04554940 · 20 enrolled · Australia, United Kingdom
  8. Mar 16, 2023Phase 1 study in AchondroplasiaNCT05813314 · 36 enrolled · United States
  9. Apr 19, 2024Phase 2 study in Idiopathic Short StatureNCT06382155 · 100 planned · United States, Australia, France and more
  10. Jun 7, 2024Phase 3 study in HypochondroplasiaNCT06455059 · 81 enrolled · United States, Australia, Canada and more
  11. Oct 30, 2024Phase 2 study in Noonan SyndromeNCT06668805 · 18 enrolled · United States, Australia, Canada and more
  12. Jun 27, 2025Phase 3 study in HypochondroplasiaNCT07073014 · 140 planned · United States, Australia, Canada and more
  13. Jul 29, 2025Phase 2 study in HypochondroplasiaNCT07126262 · 60 planned · United States, Australia, France and more
  14. Nov 13, 2026Phase 2 study terminatedStudy stoppedNCT06668805 · “BioMarin has decided to discontinue the study after assessing a number of factors, including study feasibility and the current treatment …”

Ahead

  1. Dec 2027Primary completion: phase 2 study in AchondroplasiaNCT04554940
  2. Dec 2027Primary completion: phase 2 study in AchondroplasiaNCT02724228
  3. Jun 30, 2028Primary completion: phase 2 study in HypochondroplasiaNCT07126262
  4. Jun 2031Primary completion: phase 3 study in AchondroplasiaNCT03424018

TargetBeta

NPR2 →read by rule
“Atrial natriuretic peptide receptor B binding agent”ChEMBL 37, by rule

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07126262Hypochondroplasia · United States, Australia, France and more2RecruitingJun 30, 202860
NCT07073014Hypochondroplasia · United States, Australia, Canada and more3By invitationOct 2044140
NCT06668805Noonan Syndrome · United States, Australia, Canada and more2TerminatedSep 16, 202618
NCT06455059Hypochondroplasia · United States, Australia, Canada and more3CompletedApr 23, 202681
NCT06382155Idiopathic Short Stature · United States, Australia, France and more2RecruitingJun 2026100
NCT05813314Achondroplasia · United States1TerminatedJun 14, 202336
NCT04554940Achondroplasia · Australia, United Kingdom2Active, not recruitingDec 202720
NCT03989947Achondroplasia · United States, Australia, Japan and more2Active, not recruitingMay 203873
NCT03583697Achondroplasia · United States, Australia, Japan and more2CompletedJan 26, 202275
NCT03424018Achondroplasia · United States, Australia, Germany and more3Active, not recruitingJun 2031119
NCT03197766Achondroplasia · United States, Australia, Germany and more3CompletedOct 30, 2019121
NCT02724228Achondroplasia · United States, Australia, France and more2Active, not recruitingDec 202730
NCT02055157Achondroplasia · United States, Australia, France and more2CompletedOct 2, 201735
NCT01590446Achondroplasia · United States1CompletedJun 201274

How it is read

Names in the registry

  • “BMN 111”, 6 entries
  • “Vosoritide”, 3 entries
  • “Vosoritide Injection”, 2 entries
  • “vosoritide”, 1 entry
  • “Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.